MADAN, MOSSMAN & SRIRAM, P.C.

Attorneys At Law

2603 Augusta Drive, Suite 700, Houston, Texas 77057-5638 713 266-1130 Fax 713 266-8510

FACSIMILE COVER SHEET

RECEIVED
CENTRAL FAX CENTER

DEC 1 2 2005

DATE:

December 12, 2005

TO:

Examiner Michele C. Flood

COMPANY OR FIRM:

PTO

FACSIMILE NO.:

(571) 273-8300

FROM:

Beth Pearson-Naul for Gene L. Tyler

RE:

Serial No.: 10/809,645 Docket No.: KSP-1001US

Title: "Herbal Extract and Compound Lupinoside and Its

Analogues as Anti-Diabetic Type II Drugs from Plant

Pueraria Tuberosa"

NUMBER OF PAGES INCLUDING THIS COVER SHEET: 3

IF ANY OF THESE PAGES ARE NOT RECEIVED, PLEASE CALL BETH AT (713) 266-1130, ext. 117

CERTIFICATE OF FACSIMILE TRANSMISSION

I hereby certify that this correspondence (Response to Office Action), is being transmitted by facsimile to the Official Patent Application Related Correspondence, facsimile no. (571) 273-8300 on this 12th day of December, 2005.

Beth Pearson-Naul

CONFIDENTIALITY NOTICE

The documents included in this facsimile may contain information that is confidential or privileged, or both, and is intended only for the use of the individual or entity named on this facsimile cover letter. Any disclosure, copying, distribution, dissemination, or use of this information by any person other than the intended recipient is prohibited. If you have received this facsimile in error, please notify us by collect telephone call at (713) 266-1130 so that we can arrange for either the retrieval of the transmitted documents at no cost to you, or destruction of the transmitted documents.

RECEIVED CENTRAL FAX CENTER

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

DEC 12 2005

APPLICANTS: Debleena Dey, et al.

SERIAL NO.: 10/809,645

FILED: 3/25/2005

TITLE: Herbal Extract and Compound

Group Art Unit: 1655

Examiner: Michele C. Flood

Atty. Docket: KSP-1001US

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

RESPONSE TO OFFICE ACTION DATED NOVEMBER 15, 2005

This is in response to the Office Action, dated November 15, 2005 for the aboveidentified patent application.

Remarks begin at page 2.